{"id":52301,"date":"2023-09-20T09:31:48","date_gmt":"2023-09-20T09:31:48","guid":{"rendered":"https:\/\/medsname.com\/natdac\/"},"modified":"2026-05-05T05:21:56","modified_gmt":"2026-05-05T05:21:56","slug":"natdac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/natdac\/","title":{"rendered":"Natdac"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">Rychl\u00e1 odpov\u011b\u010f<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Natdac<\/strong> \u2014 daclatasvir 30\/60 mg (Natco Pharma). Pan-genotypick\u00fd inhibitor NS5A \u2014 pou\u017e\u00edvan\u00fd v kombinaci s sofosbuvirem k l\u00e9\u010db\u011b hepatitidy C nap\u0159\u00ed\u010d genotypy 1-6, zejm\u00e9na genotypu 3, kde z\u016fst\u00e1v\u00e1 preferovanou volbou. Generick\u00e1 verze p\u0159\u00edpravku BMS Daklinza.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/li>\n<li>Diskr\u00e9tn\u00ed balen\u00ed v oby\u010dejn\u00e9 ob\u00e1lce<\/li>\n<li>Dod\u00e1n\u00ed po cel\u00e9m sv\u011bt\u011b<\/li>\n<li>Hodnoceno v\u00edce ne\u017e 1 400 z\u00e1kazn\u00edky (<a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">\u010d\u00edst recenze<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>Z\u00e1ruka op\u011btovn\u00e9ho zasl\u00e1n\u00ed:<\/strong> pokud va\u0161e objedn\u00e1vka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f od odesl\u00e1n\u00ed, za\u0161leme ji znovu bez dal\u0161\u00edch n\u00e1klad\u016f. <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">P\u0159e\u010d\u00edst podm\u00ednky<\/a>.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Natdac je expedov\u00e1n od v\u00fdrobce certifikovan\u00e9ho WHO-GMP v neutr\u00e1ln\u00edm balen\u00ed, fakturace prob\u00edh\u00e1 p\u0159es regulovan\u00e9ho platebn\u00edho procesora (na v\u00fdpisu z \u00fa\u010dtu se zobraz\u00ed regulovan\u00fd platebn\u00ed procesor \u2014 nikdy MedsBase nebo n\u00e1zev l\u00e9ku). Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed 20denn\u00ed z\u00e1rukou na p\u0159eposl\u00e1n\u00ed.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>FDA \u010dern\u00fd r\u00e1me\u010dek: reaktivace HBV<\/strong><br \/>V\u0161echny DAA terapie hepatitidy C nesou varov\u00e1n\u00ed FDA v \u010dern\u00e9m r\u00e1me\u010dku ohledn\u011b reaktivace viru hepatitidy B u pacient\u016f s koinfekc\u00ed HCV + HBV (co\u017e m\u016f\u017ee b\u00fdt fulminantn\u00ed a fat\u00e1ln\u00ed). P\u0159ed zah\u00e1jen\u00edm jak\u00e9hokoli DAA re\u017eimu testujte HBsAg a HBV DNA. Pokud je HBV pozitivn\u00ed, hepatolog mus\u00ed zajistit spole\u010dnou l\u00e9\u010dbu nebo profylaktickou anti-HBV terapii.<\/div>\n<h2>Jak daclatasvir funguje<\/h2>\n<p>NS5A je multifunk\u010dn\u00ed protein HCV nezbytn\u00fd pro replikaci virov\u00e9 RNA a sestaven\u00ed virionu. Daclatasvir se v\u00e1\u017ee na NS5A a naru\u0161uje jak tvorbu replika\u010dn\u00edho komplexu, tak sestaven\u00ed virionu. Je \u00fa\u010dinn\u00fd, pan-genotypick\u00fd a dob\u0159e sn\u00e1\u0161en\u00fd.<\/p>\n<p>Daclatasvir se v\u017edy pod\u00e1v\u00e1 s sofosbuvirem (nebo jinou nukleotidovou kostrou) \u2014 nikdy jako monoterapie. Kombinace dosahuje SVR12 u \u226595 % pacient\u016f nap\u0159\u00ed\u010d genotypy, v\u010detn\u011b genotypu 3 (kde jsou re\u017eimy zalo\u017een\u00e9 na ledipasviru m\u00e9n\u011b \u00fa\u010dinn\u00e9).<\/p>\n<p>Standardn\u00ed d\u00e1vka je 60 mg jednou denn\u011b. P\u0159i siln\u00fdch inhibitorech CYP3A4 sn\u00ed\u017eit na 30 mg; p\u0159i st\u0159edn\u00edch induktorech (pokud se jim nelze vyhnout) zv\u00fd\u0161it na 90 mg.<\/p>\n<h2>Tabulka d\u00e9lky l\u00e9\u010dby<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:12px 0;\">\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;\">Populace<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;\">Re\u017eim<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Genotyp 1 \/ 4 \/ 5 \/ 6, l\u00e9\u010debn\u011b naivn\u00ed, bez cirh\u00f3zy<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 t\u00fddn\u016f (obvykle v kombinaci s inhibitorem NS5A)<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Genotyp 2, bez cirh\u00f3zy<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 t\u00fddn\u016f (sofosbuvir + ribavirin nebo sofosbuvir + daclatasvir)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Genotyp 3, bez cirh\u00f3zy<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 t\u00fddn\u016f sofosbuvir + daclatasvir (sofosbuvir + velpatasvir je pan-genotypov\u00e1 alternativa)<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Kompensovan\u00e1 cirh\u00f3za (jak\u00fdkoli genotyp)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 t\u00fddn\u016f kombinace DAA + ribavirin ve vybran\u00fdch p\u0159\u00edpadech; 24 t\u00fddn\u016f u pacient\u016f s p\u0159edchoz\u00ed l\u00e9\u010dbou<\/td>\n<\/tr>\n<\/table>\n<p>Setrval\u00e1 virologick\u00e1 odpov\u011b\u010f 12 t\u00fddn\u016f po ukon\u010den\u00ed l\u00e9\u010dby (SVR12) je ukazatelem vyl\u00e9\u010den\u00ed \u2014 dosahuje se u ~95-99 % pacient\u016f u modern\u00edch re\u017eim\u016f DAA.<\/p>\n<h2>V\u00fdznamn\u00e9 l\u00e9kov\u00e9 interakce<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:12px 0;\">\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;\">L\u00e9k<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;\">\u00da\u010dinek a p\u016fsoben\u00ed<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Amiodaron + sofosbuvir<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\"><strong>Varov\u00e1n\u00ed FDA \u2014 hl\u00e1\u0161eny symptomatick\u00e9 bradykardie a \u00famrt\u00ed.<\/strong> Kombinaci se vyhn\u011bte. Pokud je to nevyhnuteln\u00e9, je nutn\u00fd nemocni\u010dn\u00ed kardiologick\u00fd monitoring.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">PPI (omeprazol, pantoprazol)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Sni\u017euj\u00ed absorpci ledipasviru (z\u00e1visl\u00e9 na pH). Re\u017eimy obsahuj\u00edc\u00ed ledipasvir u\u017e\u00edvejte s j\u00eddlem a PPI v odstupu \u22654 hodin, nebo m\u00edsto nich pou\u017eijte H2 blok\u00e1tory\/antacida. Velpatasvir je tak\u00e9 citliv\u00fd na pH \u2014 stejn\u00e9 doporu\u010den\u00ed.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Rifampicin, rifabutin<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Siln\u00e9 induktory CYP3A4 + P-gp \u2014 v\u00fdrazn\u011b sni\u017euj\u00ed hladiny DAA. Kombinaci se vyhn\u011bte.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">T\u0159ezalka te\u010dkovan\u00e1<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Indukce CYP3A4 \u2014 sni\u017euje hladiny DAA a zvy\u0161uje riziko selh\u00e1n\u00ed l\u00e9\u010dby. Vyhn\u011bte se po celou dobu terapie.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Fenytoin, karbamazepin, oxkarbazepin<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Antikonvulziva s induk\u010dn\u00edm \u00fa\u010dinkem \u2014 v\u00fdrazn\u011b sni\u017euj\u00ed hladiny DAA. P\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby hepatitidy C p\u0159ejd\u011bte na neindukuj\u00edc\u00ed antiepileptikum (lamotrigin, levetiracetam).<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Statiny (rosuvastatin, atorvastatin)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Variabiln\u00ed zv\u00fd\u0161en\u00ed hladin statin\u016f. Pou\u017e\u00edvejte nejni\u017e\u0161\u00ed d\u00e1vku; rosuvastatin se obecn\u011b vyh\u00fdb\u00e1 p\u0159i kombinaci se sof+vel; atorvastatin je p\u0159ijateln\u00fd v n\u00edzk\u00e9 d\u00e1vce.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Warfarin<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">INR m\u016f\u017ee kol\u00edsat p\u0159i regeneraci jater b\u011bhem l\u00e9\u010dby DAA. Monitorujte INR t\u00fddn\u011b do stabilizace.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">HIV antiretrovirotika<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Tenofovir + ledipasvir \u2014 zv\u00fd\u0161en\u00e1 expozice tenofoviru; monitorujte ren\u00e1ln\u00ed funkci. Efavirenz sni\u017euje hladiny velpatasviru \u2014 vyhn\u011bte se kombinaci. HCV-HIV koinfekce v\u017edy vy\u017eaduje konzultaci specialisty na infek\u010dn\u00ed onemocn\u011bn\u00ed\/hepatologii.<\/td>\n<\/tr>\n<\/table>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>Jak\u00e1 je m\u00edra vyl\u00e9\u010den\u00ed?<\/h3>\n<p>Modern\u00ed re\u017eimy DAA dosahuj\u00ed setrval\u00e9 virologick\u00e9 odpov\u011bdi (SVR12) \u2014 nedetekovateln\u00e1 HCV RNA 12 t\u00fddn\u016f po l\u00e9\u010db\u011b, pova\u017eov\u00e1no za vyl\u00e9\u010den\u00ed \u2014 u 95-99 % pacient\u016f nap\u0159\u00ed\u010d genotypy. Cirh\u00f3za, p\u0159edchoz\u00ed selh\u00e1n\u00ed l\u00e9\u010dby a HCV\/HIV koinfekce m\u00edrn\u011b sni\u017euj\u00ed m\u00edru odpov\u011bdi.<\/p>\n<h3>Co je SVR12?<\/h3>\n<p>Setrval\u00e1 virologick\u00e1 odpov\u011b\u010f 12 t\u00fddn\u016f po l\u00e9\u010db\u011b. Po dokon\u010den\u00ed 12t\u00fddenn\u00edho cyklu DAA se HCV RNA kontroluje 12 t\u00fddn\u016f po posledn\u00ed d\u00e1vce. Nedetekovateln\u00e1 = vyl\u00e9\u010den\u00ed. Pozdn\u00ed relaps po SVR12 je &lt;1 %.<\/p>\n<h3>Budu pot\u0159ebovat kontroln\u00ed test?<\/h3>\n<p>Ano. HCV RNA na konci l\u00e9\u010dby + 12 t\u00fddn\u016f po l\u00e9\u010db\u011b potvrd\u00ed SVR12. Biochemie jater a FibroScan\/zobrazovac\u00ed metody za 6-12 m\u011bs\u00edc\u016f u pacient\u016f s cirh\u00f3zou k posouzen\u00ed regrese. I po vyl\u00e9\u010den\u00ed screening na hepatocelul\u00e1rn\u00ed karcinom ka\u017ed\u00fdch 6 m\u011bs\u00edc\u016f, pokud je p\u0159\u00edtomna cirh\u00f3za.<\/p>\n<h3>A co hepatitida B?<\/h3>\n<p>V\u0161echny DAA nesou \u010dernou v\u00fdstrahu FDA kv\u016fli reaktivaci HBV u pacient\u016f s koinfekc\u00ed HCV+HBV. P\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby je nutn\u00e9 testovat HBsAg a HBV DNA. Pokud je HBV pozitivn\u00ed, mus\u00ed b\u00fdt l\u00e9\u010dba koordinov\u00e1na s hepatologem.<\/p>\n<h3>M\u016f\u017eu p\u00edt alkohol?<\/h3>\n<p>B\u011bhem l\u00e9\u010dby a ide\u00e1ln\u011b 6\u201312 m\u011bs\u00edc\u016f po n\u00ed se vyh\u00fdbejte alkoholu. Aktivn\u00ed u\u017e\u00edv\u00e1n\u00ed alkoholu nen\u00ed kontraindikac\u00ed pro l\u00e9\u010dbu DAA, ale zhor\u0161uje dlouhodob\u00e9 v\u00fdsledky po\u0161kozen\u00ed jater bez ohledu na stav HCV.<\/p>\n<h3>T\u011bhotenstv\u00ed?<\/h3>\n<p>Sofosbuvir je FDA kategorie B pro t\u011bhotenstv\u00ed (nejsou dostupn\u00e1 data o teratogenit\u011b u lid\u00ed; data u zv\u00ed\u0159at jsou uklid\u0148uj\u00edc\u00ed). V\u011bt\u0161ina DAA nem\u00e1 dostate\u010dn\u00e1 data o t\u011bhotenstv\u00ed. B\u011bhem l\u00e9\u010dby je standardem antikoncepce. Ribavirin (pou\u017e\u00edvan\u00fd jako dopln\u011bk) je siln\u011b teratogenn\u00ed \u2014 oba partne\u0159i mus\u00ed pou\u017e\u00edvat antikoncepci b\u011bhem l\u00e9\u010dby ribavirinem a 6 m\u011bs\u00edc\u016f po n\u00ed.<\/p>\n<h3>Vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n<p>Modern\u00ed DAA jsou obecn\u011b dob\u0159e sn\u00e1\u0161eny. \u010cast\u00e9: \u00fanava, bolesti hlavy, nevolnost, nespavost. M\u00e9n\u011b \u010dast\u00e9: vyr\u00e1\u017eka, pr\u016fjem. Vedlej\u0161\u00ed \u00fa\u010dinky vedouc\u00ed k ukon\u010den\u00ed l\u00e9\u010dby jsou vz\u00e1cn\u00e9.<\/p>\n<h3>Generick\u00fd vs. origin\u00e1ln\u00ed \u2014 z\u00e1le\u017e\u00ed na tom?<\/h3>\n<p>Indick\u00e9 generick\u00e9 DAA jsou vyr\u00e1b\u011bny na z\u00e1klad\u011b dobrovoln\u00fdch licenc\u00ed od Gileadu (Sovaldi, Harvoni, Epclusa), AbbVie a BMS. Jsou bioekvivalentn\u00ed a obsahuj\u00ed stejnou molekulu. Mnoho studi\u00ed z re\u00e1ln\u00e9 praxe (CT2, Plus-Asia) ukazuje stejn\u00e9 m\u00edry SVR12 jako u origin\u00e1ln\u00edch produkt\u016f.<\/p>\n<h3>L\u00e9kov\u00e9 interakce, na kter\u00e9 si d\u00e1t pozor?<\/h3>\n<p>Nejd\u016fle\u017eit\u011bj\u0161\u00ed: amiodaron + sofosbuvir (\u010dern\u00e1 v\u00fdstraha pro bradykardii), rifampicin (sni\u017euje hladiny DAA), PPI (sni\u017euj\u00ed \u00fa\u010dinek ledipasviru\/velpatasviru), u koinfekce HIV jsou nutn\u00e9 \u00fapravy ARV. V\u017edy sd\u011blte v\u0161echny l\u00e9ky v\u010detn\u011b bylinn\u00fdch\/voln\u011b prodejn\u00fdch.<\/p>\n<h3>Po vyl\u00e9\u010den\u00ed \u2014 mohu se znovu nakazit HCV?<\/h3>\n<p>Ano. SVR odstran\u00ed sou\u010dasnou infekci, ale neposkytuje budouc\u00ed imunitu. Reinfekce novou expozic\u00ed (IV u\u017e\u00edv\u00e1n\u00ed drog, nebezpe\u010dn\u00e9 l\u00e9ka\u0159sk\u00e9 z\u00e1kroky, MSM s koinfekc\u00ed HIV) je mo\u017en\u00e1. Poskytn\u011bte poradenstv\u00ed o prevenci a nab\u00eddn\u011bte testov\u00e1n\u00ed HCV RNA p\u0159i jak\u00e9koli nov\u00e9 rizikov\u00e9 expozici.<\/p>\n<p class=\"medsbase-link-boost-2026-05-05\" data-marker=\"mb-link-boost-hepcinat-lp\"><a href=\"https:\/\/medsbase.com\/cs\/natdac\/\">Natdac<\/a> (daclatasvir 60 mg) se u\u017e\u00edv\u00e1 spolu s sofosbuvirem u n\u011bkolika genotyp\u016f, ale pro genotypy 1, 4, 5 a 6 jedna tableta <a href=\"https:\/\/medsbase.com\/cs\/hepcinat-lp\/\">Hepcinat LP (sofosbuvir 400 mg + ledipasvir 90 mg)<\/a> kombinuje ob\u011b \u00fa\u010dinn\u00e9 l\u00e1tky a zlep\u0161uje adherenci oproti denn\u00edmu re\u017eimu se dv\u011bma tabletami.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed l\u00e9ky na hepatitidu C<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/myhep\/\">MyHep<\/a> \u2014 sofosbuvir 400 mg \u2014 kombinovan\u00fd partner pro daclatasvir<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/hepcinat\/\">Hepcinat<\/a> \u2014 sofosbuvir 400 mg \u2014 zna\u010dka Natco<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/hepcvir\/\">Hepcvir<\/a> \u2014 sofosbuvir 400 mg \u2014 zna\u010dka Cipla<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/velpanat\/\">Velpanat<\/a> \u2014 sofosbuvir + velpatasvir \u2014 alternativn\u00ed pan-genotypick\u00e1 jednoduch\u00e1 tableta<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ledifos\/\">Ledifos<\/a> \u2014 sofosbuvir + ledipasvir pro genotypy 1, 4, 5, 6<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Tato str\u00e1nka slou\u017e\u00ed pouze pro informaci a nenahrazuje l\u00e9ka\u0159skou p\u00e9\u010di kvalifikovan\u00e9ho odborn\u00edka. Proberte jak\u00e9koli nov\u00e9 l\u00e9ky se sv\u00fdm l\u00e9ka\u0159em nebo l\u00e9k\u00e1rn\u00edkem.<\/div>","protected":false},"excerpt":{"rendered":"<p>Natdac (Daclatasvir 30\/60 mg) \u2014 pan-genotypick\u00fd inhibitor NS5A od spole\u010dnosti Natco pro chronickou hepatitidu C. Kombinuje se s sofosbuvirem; preferovan\u00e1 z\u00e1kladn\u00ed l\u00e9\u010dba pro genotyp 3.<\/p>","protected":false},"featured_media":52302,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334],"product_tag":[],"class_list":{"0":"post-52301","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/52301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=52301"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/52302"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=52301"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=52301"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=52301"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=52301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}